Madrigal Pharmaceuticals (MDGL) Operating Leases (2019 - 2026)

Madrigal Pharmaceuticals (MDGL) has 8 years of Operating Leases data on file, last reported at $5.3 million in Q1 2026.

• On a quarterly basis, Operating Leases rose 604.53% year-over-year to $5.3 million in Q1 2026; TTM through Mar 2026 was $5.3 million, a 604.53% increase from a year earlier, with the FY2025 full-year figure at $6.7 million, up 561.2% from the prior year.
• Operating Leases for Q1 2026 stood at $5.3 million, down from $6.7 million in the prior quarter.
• Over the last five years, Operating Leases for MDGL reached as high as $6.7 million in Q4 2025 and fell as low as $71000.0 in Q3 2022.
• Historically, Operating Leases has averaged $2.1 million across 5 years, with a median of $1.1 million in 2024.
• Across the five-year window, Operating Leases slumped 85.54% in 2022 and jumped 1763.38% in 2023, its largest moves.
• Year by year, Operating Leases stood at $71000.0 in 2022, then surged by 1570.42% to $1.2 million in 2023, then retreated by 14.17% to $1.0 million in 2024, then jumped by 561.2% to $6.7 million in 2025, then dropped by 21.5% to $5.3 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $5.3 million in Q1 2026, $6.7 million in Q4 2025, and $5.6 million in Q3 2025.